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Trichomonas vaginalis (Tv) is a causative agent of
worldwide spread sexually transmitted disease, particu-
larly affecting underdeveloped all segments of the popu-
lation. Metronidazole is by far the most prescribed drug
for the treatment of trichomoniasis. However, the
appearance of drug resistant has led to the appearance
of new drug alternatives. That is why the development
o fr e l i a b l ea n ds t a n d a r dt e s tf o rt h ee v a l u a t i o nc l i n i c a l
isolates sensitivity is necessary for routine laboratory
practice. Traditionally used for this purpose the method
of serial dilutions is laborious and time consuming.
A simple and practical method can be used for screen-
ing of sensitivity of Tv to anti-trichomonas drugs. This
test contains of nutrient medium, special device for
microscopic study and 8-well strip with drugs in fixed
concentration which was previously determined. Using
ten laboratory strains Tv it was found that minimal inhi-
bitory concentrations (MIC’s) were the following (µg/
ml): metronidazole (5), secnidazole (2,5), tinidazole (2,5),
nimorazole (2,5), ornidazole (2,5), clotrimazole (15),
nifuratel (1,25). Viability definition of Tv was performed
using trypan blue stain and subculturing on a medium
without any drugs. The scheme of assay was the follow-
ing: poured into eight strip wells nutrient medium,
inoculum cells trichomonads added and do microscopic
examination after 48 hours of incubation under 37°C.
The microscopic technique is based on the use of a spe-
cial device consisting of eight micro chambers which
allows examining eight probes at a one operation. 99
patients who had been confirmed of having chronical
trichomoniasis were examined with this test. The test
sensitivity to metronidazole, secnidazole, tinidazole,
nimorazole, ornidazole, clotrimazole and nifuratel was
performed as described earlier.
Results of sensitivity test with clinical samples were
divided into three groups: resistance (R) - maintaining
the viability of 50% or more trichomonads cells, sensitiv-
ity I (SI) - presence of 25% or less viable cells, sensitivity
II (SII) – all cells lysis. The results showed the following
sensitivity samples distribution: metronidazole - 23 (R),
47 (SI), 29 (SII), tinidazole - 58 (R), 30 (SI), 11 (SII),
nimorazol - 71 (R), 19 (SI), 9 (SII), ornidazole - 51 (R),
41 (SI), 7 (SII), seknidazol - 57 (R), 28 (SI), 17 (SII), clo-
trimazole - 60 (R), 32 (SI), 7 (SII), nifuratel - 32 (R), 52
(SI), 15 (SII). One strain possessed multiple resistance.
Thus, the frequency of strains detection resistant to
the action of drugs quite high, that argues the need to
determine it “in vitro” for the choice of subsequent
therapy.
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